Safety and Efficacy of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Pegfilgrastim in Japanese Patients with Advanced or Metastatic Urothelial Carcinoma
The ddMVAC with pegfilgrastim (3.6 mg) reduced injection-related patient burden, caused fewer grade ≥3 adverse events, and demonstrated similar efficacy when compared to the original ddMVAC regimen that used granulocyte colony-stimulating factor for 7 consecutive days.
Authors
- Takahiro HARANO
- Masaomi Ikeda (ORCID: https://orcid.org/0000-0003-1017-9799)
- Daisuke Ishii (ORCID: https://orcid.org/0009-0005-2966-6476)
- Soichiro Shimura (ORCID: https://orcid.org/0000-0001-6798-7442)
- Dai Koguchi (ORCID: https://orcid.org/0000-0001-8057-8221)
- Hideyasu Tsumura (ORCID: https://orcid.org/0000-0002-8962-2345)
- Shuhei Hirano (ORCID: https://orcid.org/0009-0007-6851-8665)
- Satoshi Okuda (ORCID: https://orcid.org/0000-0002-3774-0294)
- Kazumasa Matsumoto (ORCID: https://orcid.org/0009-0007-9465-5161)
- Minoru Toyoda
Institutions
- Kitasato University (JP)
Publication Details
- Journal
- Chemotherapy
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1159/000543333
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.15
Funders
- Kitasato University